

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

Service Category:

- | | |
|--|---|
| <input type="checkbox"/> Anesthesia | <input type="checkbox"/> Medicine Services and Procedures |
| <input type="checkbox"/> Surgery | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures | <input type="checkbox"/> DME/Prosthetics or Supplies |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Other: Part B Drugs |

Service Description:

This document addresses the use of Elevidys, an adeno-associated virus vector-based gene therapy, approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients 4 years of age and older with a confirmed mutation in the *DMD* gene.

ELEVIDYS (Delandistrogene moxeparvovec-rokl) is a suspension approved for intravenous administration only, with a dosing regimen based on the patient’s body weight.

Background Information:

Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene. This genetic disorder, results in progressive and irreversible muscle weakness and damage. The disease typically manifests in early childhood, with initial symptoms including difficulty walking, enlarged calves, difficulty standing from a supine position, frequent falls, fatigue, and loss of muscle strength. In the initial stages of Duchenne muscular dystrophy, the disease primarily affects the muscles of the hips and thighs, leading to difficulties with standing, climbing stairs, and maintaining balance. As the disease progresses, these difficulties often result in complete loss of ambulation. In later years of age, the disease affects cardiac and respiratory function, with the potential for life-threatening complications.

Although Duchenne muscular dystrophy (DMD) is considered an irreversible condition, several clinical management strategies have been developed with the objective of slowing the progression of the disease. The following table illustrates the typical clinical signs and symptoms progression of Duchenne muscular dystrophy (DMD) at different age ranges. It should be considered that DMD is a heterogeneous disease, meaning that the progression of Duchenne varies significantly between patients.

Table 1. Disease Progression in Duchenne Muscular Dystrophy (DMD)

| Age | Symptoms Description |
|------------------------------------|--|
| Commonly observed in 0 to 4 years | <ul style="list-style-type: none"> • Soon after birth inflammation • Muscle fibrosis seen as early as 1 year of age • Motor delays • Other delays, such as a speech delay |
| Commonly observed in 5 to 7 years | <ul style="list-style-type: none"> • Progressive muscular weakness • Enlarged calves • Toe walking • Difficulty standing from a supine position • Muscle fat accumulation |
| Commonly observed in 8 to 11 years | <ul style="list-style-type: none"> • Delays in the motor milestones • Decreased ability to walk |

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

| | |
|---------------------------------------|---|
| Commonly observed in 12 to 19 years | <ul style="list-style-type: none"> Part-time wheelchair use Decreased upper limb, respiratory, and cardiac function Loss of ambulation Frequent need for ventilatory support Inability to perform activities of daily living |
| Commonly observed in teens and beyond | <ul style="list-style-type: none"> Increase in cardiac dysfunction Heart failure Life expectancy significantly reduced |

An early diagnosis of Duchenne muscular dystrophy (DMD) involves a combination of genetic testing to confirm a mutation in the DMD gene and a physical assessment, as well as laboratory tests such as elevated serum creatine kinase, which indicates muscle damage. In patients aged between 0 and 3 years, creatine kinase (CK) levels are greater than 305 U/L (with a normal range of 60-305 U/L). In patients aged between 4 and 6 years, CK levels above 230 U/L are indicative of an abnormally high level.

For patients who are ambulatory, a rating scale called the North Star Ambulatory Assessment (NSAA) is used to quantify the effect of Duchenne muscular dystrophy on a patient's ability to perform activities of daily living requiring ambulatory capabilities. The NSAA is a validated rating scale that comprises 17 assessments, including: stand, walk, rise from a chair, climb, and descend a box step, gets to sitting, jump, run, rise from floor, lift head, and hop on the legs. These assessments evaluate ability and assistance requirement to perform the task. Each of the 17 assessments is scored on a scale of 0, 1, or 2, depending on the patient's performance of the designated activity. A score of 0 indicates that the subject is unable to perform the task. A score of 1 indicates that the subject is able to perform the task but required assistance or completed the task independently but with evident difficulty. A score of 2 indicates that the subject is able to perform the task independently and without difficulty. A higher total score is indicative of better functional performance. For patients younger than five years old, the NSAA reorders the tasks to align better with age-appropriate abilities and scoring as described in the table below. This approach considers the typical progression of motor skill development in children.

Table 2. NSAA highest score according to patient age

| Age (years) | Highest score and assessment items |
|-------------|---|
| 3 | Highest score: 16 Assessment: 8 items |
| 3 ½ | Highest score: 26 Assessment: 13 items |
| 4 and older | Highest score: 34 Assessment: 17 items |

The Duchenne muscular dystrophy treatment involves a combination of pharmacologic and non-pharmacologic therapies aimed at managing symptoms, preserving muscle function, and treating complications. Corticosteroids, such as Prednisone and Deflazacort (Emflaza), are commonly used to reduce muscle degeneration. In addition, exon-skipping therapies such as Casimersen (Amondys 45), Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), and Vitolarsen (Viltepso) are designed to bypass specific mutated exons in the DMD gene transcript to mitigate the effects of mutations in patients with specific genotypes. Physical therapy is essential to maintain mobility and

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

quality of life for people with DMD. Emerging gene therapies such as Elevidys represent a new approach to DMD treatment by targeting the DMD gene.

Elevidys (delandistrogene moxeparvovec-rokl) is the first gene therapy approved by the FDA for the treatment of Duchenne muscular dystrophy. This vector-based gene therapy is a single intravenous treatment indicated for ambulatory patients 4 years of age and older with a confirmed mutation in the DMD gene. Elevidys is designed to address the absent functional dystrophin in DMD, a protein that stabilizes muscle fibers. Elevidys is contraindicated in patients with deletions in exon 8 and/or exon 9, which may increase the risk of an immune-mediated myositis reaction. Anti-AAV antibody titers must be measured as patients eligible for Elevidys must have anti-AAVrh74 total binding antibody titers <1:400. The recommended dosage of Elevidys is based on the patient's weight, depending on whether it is less or more than 70 kg. It is supplied as a 10 mL single-use vial in a customized kit based on the patient's dosing requirements. Elevidys may cause infusion-related reactions, acute severe liver injury, immune-mediated myositis, and myocarditis. As part of the administration process, it is recommended that patients receive systemic corticosteroid treatment before and after Elevidys to reduce the risk of an immune response.

To date, benefits of Elevidys have been demonstrated in two double-blind, placebo-controlled studies (Study 1 [NCT 03769116] and Study 3 [NCT 05096221]) and one open-label study (Study 2 [NCT 04626674]). Relevant inclusion criteria are shown in the table below.

Table 3. Clinical Trials Evaluating Elevidys in Duchenne Muscular Dystrophy (DMD).

| Trial | Diagnosis | Study population | Age |
|---------------------------|---|------------------------------|--|
| Study 1 [NCT03769116] | Confirmed frameshift mutation, or a premature stop codon mutation between exons 18 to 58 in the DMD gene. | 41 male ambulatory patients | 4 through 7 years |
| Study 2 [NCT 04626674] | Cohorts 1, 2 and 3: Confirmed frameshift, splice site or premature stop codon mutation anywhere in the DMD gene. Cohort 4: Patients with mutations in the DMD gene starting at or after exon 18. Cohort 5: Mutations that partially or fully overlap with exons 1-17 in the DMD gene. | 48 male patients (5 cohorts) | Cohorts 1, 2, 4 and 5a: 40 ambulatory patients 3 to 12 years of age. Cohorts 3 and 5b: 8 non-ambulatory patients 10 to 20 years of age. |
| Study 3 [NCT 05096221] | Confirmed frameshift, splice site, premature stop codon, or other disease-causing mutation | 125 ambulatory male patients | 4 through 7 years |

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

| | | | |
|--|--|--|--|
| | in the DMD gene starting at or after exon 18 | | |
|--|--|--|--|

Approved Indications

- A. ELEVIDYS is indicated or the treatment of patients 4 years of age and older with Duchenne muscular dystrophy (DMD) who are ambulatory and have a confirmed mutation in the *DMD* gene.

Other Uses

- A. None.

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Elevidys® (delandistrogene moxeparvovec-rokl)

*Note: Per FDA labeling updated November 14, 2025, ELEVIDYS is indicated only for ambulatory patients ≥4 years of age with a confirmed DMD gene mutation; the non-ambulatory indication was removed following reports of fatal acute liver failure. Coverage for non-ambulatory use is not consistent with current FDA-approved labeling.

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

Initial request of Elevidys may be approved if the following criteria are met:

- i. Elevidys is prescribed by a neurologist or neuromuscular specialist; **AND**
- ii. Documentation provided that evidence a confirmatory diagnosis by:
 - A. Patient is four (4) years of age or more; **AND**
 - B. Genetic test that confirms the mutation in the Duchenne muscular dystrophy (DMD) gene; **AND**
 - C. Genetic test confirms that the mutation is not a deletion in exon 8 and/or exon 9 in the DMD gene; **AND**
 - D. Patient is ambulatory at baseline (per treating specialist documentation).
- iii. Documentation evidencing:
 - A. Anti-AAVrh74 total binding antibody titers <1:400; **AND**
 - B. Baseline clinical and laboratory assessment completed prior to infusion, including (at minimum): AST, ALT, GGT, albumin, aPTT, INR, total bilirubin; platelet count; and troponin-I; **AND**
 - C. Patient does not meet FDA “Limitations of Use” risk factors, including:
 - Preexisting liver impairment (GGT >2x ULN or total bilirubin > ULN not due to Gilbert’s syndrome) or active hepatic viral infection; **OR**
 - Recent vaccination within 4 weeks of treatment; **OR**
 - Active or recent (within 4 weeks) infection(s).
 - D. Current weight (kg) documented within the past 30 days prior to the planned infusion date and used to calculate the requested Elevidys dose (rounded to the nearest kilogram);

AND

- iv. Patient meets all the following criteria:
 - A. The prescribed dose is appropriate to the patient’s weight.

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

- Less than 70 kg: Weight based; **OR**
- 70 kg or greater: Fixed total fixed dose; **AND**

Refer to the section: “Indicated dose based on the patient’s weight for more details.

- B. Patient has not previously received Elevidys therapy; **AND**
- C. Concomitant use with exon-skipping therapies (antisense oligonucleotides) has not been established; if used, coverage will be determined case-by-case and should not be administered concurrently with Elevidys infusion; **AND**
- D. Patient will receive a corticosteroid regimen before and after infusion; **AND**
- E. Provider attests there is a monitoring plan consistent with FDA labeling, including weekly liver function monitoring for the first 3 months after infusion (and continued until unremarkable) and troponin-I monitoring weekly for the first month after infusion; **AND**
- F. Provider has instructed patient/family to maintain proximity to an appropriate healthcare facility for at least 2 months following infusion; **AND**
- v. ELEVIDYS will be administered as an intravenous infusion.
- vi. Ambulatory functional assessment (baseline documentation):
 - A. Documentation evidencing the ambulatory performance evaluation by the North Star Ambulatory Assessment (NSAA).
 - NSAA performed within the past six (6) months prior to request submission; include score and test date.

Indicated dose based on the patient’s weight

- Less than 70 kg: 1.33×10^{14} vector genomes per kilogram (vg/kg) **OR** 10 mL/kg
 - The patient's body weight should be rounded to the nearest kilogram.
 - Example: Elevidys for a 20.5 kg patient
Round to the nearest kilogram = 21 kg
 - Elevidys dose (mL) = Patient body weight (rounded to the nearest kilogram) x 10mL/kg
 - The multiplication factor 10 represents the per kilogram dose (1.33×10^{14} vg/kg) divided by the amount of vector genome copies per mL of the ELEVIDYS suspension (1.33×10^{13} vg/mL).
 - Number of Elevidys vials needed = ELEVIDYS dose (in mL) divided by 10.
 - Each Elevidys vial has a volume of 10mL (10mL/vial)
 - Round to the nearest number of vials

Calculation Example: Elevidys dose for a 20.5 kg patient.

20.5 kg rounded to the nearest kilogram = 21 kg

$$\text{Elevidys Volume: } 21 \text{ kg} \times \left(\frac{10\text{mL}}{\text{kg}}\right) = 210 \text{ mL}$$

$$\text{Elevidys vials: } 210\text{mL} \left(\frac{\text{vial}}{10 \text{ mL}}\right) = 21 \text{ vials}$$

- 70 kg or greater: 9.31×10^{15} vector genomes (vg) total fixed dose

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

B. Criteria For Continuation of Therapy

- i. MMM does not consider the continuation of Elevidys to be medically necessary. According to the product's updated clinical approved data, Elevidys is approved for single-dose administration only, and there is no recommendation for further doses.

C. Authorization Duration

- i. Initial Approval Duration: 3 months. According to the product's package label, Elevidys is administered as a single-dose intravenous infusion, and readministration is not recommended.
- ii. Reauthorization Approval Duration: N/A. MMM does not consider the readministration of Elevidys to be medically necessary, as it is intended for single-dose administration only, and administration is not advised.

Note: The dosage is based on the patient's weight. If weight changes, the dosage should be adjusted accordingly.

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Requests for Elevidys may not be approved when the above criteria (Section A: Criteria for Initial Approval) are not met or when use is not consistent with current FDA-approved labeling:
 - a. Patients with any deletion in exon 8 and/or exon 9 in the DMD gene; (Elevidys is contraindicated in patients with any deletion in exon 8 and/or exon 9) **OR**
 - b. At the time of request/infusion, patient has an active infection **OR** has had a recent infection within the past 4 weeks (ELEVIDYS should be postponed in patients with active or recent [within 4 weeks] infections) (requests may be reconsidered once infection has resolved and the 4-week window has passed, if all other criteria are met); **OR**
 - c. Use in non-ambulatory patients or any other indication not consistent with current FDA-approved labeling.

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

| Patient weight | Recommended Dose |
|------------------|--|
| Less than 70 kg | 1.33×10^{14} vector genomes per kilogram (vg/kg) OR 10 mL/kg |
| 70 kg or greater | 9.31×10^{15} vector genomes (vg) total fixed dose |
| Exceptions | |
| N/A | |

ELEVIDYS is supplied as a patient-specific kit (ten to seventy 10mL single-dose vials) to meet dosing requirements. The total number of vials in each kit is based on the patient's body weight and corresponds to the dosing requirement for that individual. Administration is by intravenous infusion over 1-2 hours at a rate of less than 10 mL/kg/hour. For further information regarding the dose and vial quantities calculations, please refer to the section: "Indicated dose based on the patient's weight" in this medical policy. Refer to the full Elevidys FDA Prescribing Information for dosage modifications, vials per kit based on patient weight, Elevidys preparation, and administration instructions.

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

| Codes | Description |
|--------|---------------------------------------|
| G71.01 | Duchenne or Becker muscular dystrophy |

HCPCS Codes:

| Codes | Description |
|-------|--|
| J1413 | Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose |

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

Reference Information:

- Birnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L. E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., Street, N., Tomezsko, J., Wagner, K. R., Ward, L. M., & Weber, D. R. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *The Lancet Neurology*, 17(3), 251–267. [https://doi.org/10.1016/s1474-4422\(18\)30024-3](https://doi.org/10.1016/s1474-4422(18)30024-3)
- Birnkrant, D. J., Bushby, K., Bann, C. M., Alman, B. A., Apkon, S. D., Blackwell, A., Case, L. E., Cripe, L., Hadjiyannakis, S., Olson, A. K., Sheehan, D. W., Bolen, J., Weber, D. R., & Ward, L. M. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *The Lancet Neurology*, 17(4), 347–361. [https://doi.org/10.1016/s1474-4422\(18\)30025-5](https://doi.org/10.1016/s1474-4422(18)30025-5)
- Duchenne.com*. (n.d.). Sarepta Therapeutics. <https://www.duchenne.com/>
- ELEVIDYS (delandistrogene moxeparvovec-rokl)*. (n.d.). ELEVIDYS (Delandistrogene Moxeparvovec-rokl). <https://www.elevidys.com/>
- Elevidys [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; August 2024.
- Mendell, J. R., Muntoni, F., McDonald, C. M., Mercuri, E. M., Ciafaloni, E., Komaki, H., Leon-Astudillo, C., Nascimento, A., Proud, C., Schara-Schmidt, U., Veerapandiyan, A., Zaidman, C. M., Guridi, M., Murphy, A. P., Reid, C., Wandel, C., Asher, D. R., Darton, E., Mason, S., . . . Rodino-Klapac, L. R. (2024). AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. *Nature Medicine*. <https://doi.org/10.1038/s41591-024-03304-z>
- Mendell, J. R., Sahenk, Z., Lehman, K. J., Lowes, L. P., Reash, N. F., Iammarino, M. A., Alfano, L. N., Lewis, S., Church, K., Shell, R., Potter, R. A., Griffin, D. A., Hogan, M., Wang, S., Mason, S., Darton, E., & Rodino-Klapac, L. R. (2023). Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. *Muscle & Nerve*, 69(1), 93–98. <https://doi.org/10.1002/mus.27955>
- Mendell, J., Sahenk, Z., Lowes, L., Reash, N., Iammarino, M., Alfano, L., Signorovitch, J., Jin, J., Gao, P., Mason, S., Elkins, J., & Rodino-Klapac, L. (2024). 425P Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD): a phase 1/2a study. *Neuromuscular Disorders*, 43, 104441.296. <https://doi.org/10.1016/j.nmd.2024.07.305>
- North Star Ambulatory Assessment*. (n.d.). Sarepta Therapeutics. Retrieved November 2024, from https://www.sarepta.com/sites/sarepta-corporate/files/2021-04/Sarepta_NSAA_Fact_Sheet.pdf
- Proud, C., McDonald, C., Mercuri, E. M., Muntoni, F., Zaidman, C., Dharia, S., & Mason, S. (2024). Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: phase 1 to phase 3 clinical trials. <https://medically.genec.com/global/en/unrestricted/neuroscience/WMS-2024/wms-2024-poster-proud-long-term-safety-and-tolerability.html>

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

11. Proud, C., Zaidman, C., McDonald, C., Day, J., Thrasher, P., Asher, D., Murphy, A., Guridi, M., Ding, K., Reid, C., Lewis, S., Magistrado-Coxen, P., Palatinsky, E., Wandel, C., Potter, R., Rodino-Klapac, L., & Mendell, J. (2024). 424P Micro-dystrophin expression and safety with delandistrogene moxeparvovec gene therapy for DMD in a broad population: phase 1B trial (ENDEAVOR). *Neuromuscular Disorders*, 43, 104441.295. <https://doi.org/10.1016/j.nmd.2024.07.304>
12. Vandeborne, K., Walter, G., Straub, V., Willcocks, R., Forbes, S., Ennamuri, S., Ding, K., Reid, C., Murphy, A., Manfrini, M., Elkins, J., & Rodino-Klapac, L. (2024). 190 Muscle MRI outcomes in patients with Duchenne muscular dystrophy treated with delandistrogene moxeparvovec: findings from EMBARK Part 1. *Neuromuscular Disorders*, 43, 104441.735. <https://doi.org/10.1016/j.nmd.2024.07.744>
13. Walter, G., Vandeborne, K., Bourke, J., Soslow, J., Mason, S., Palatinsky, E., Wandel, C., Ding, K., Reid, C., Murphy, A., Manfrini, M., Richardson, J., & Elkins, J. (2024). 428P Cardiac MRI outcomes in patients with Duchenne muscular dystrophy treated with delandistrogene moxeparvovec: findings from EMBARK Part 1. *Neuromuscular Disorders*, 43, 104441.299. <https://doi.org/10.1016/j.nmd.2024.07.308>

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

| | | | | |
|--|--|--|--|---|
| Policy Name: Delandistrogene moxeparvovec-rokl (Elevidys®) | Policy Number: MP-RX-FP-163-24 | Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth | Origination Date: 12/17/2024 Last Review Date: 5/6/2026 | Effective Date: 5/6/2026 Frequently Revision: Annual |
|--|--|--|--|---|

Policy History:

| Type of Review | Summary of Changes | P&T Approval Date | UM/CMPC Approval Date |
|-------------------------|--|-------------------|-----------------------|
| Focus Review | Updated FDA indication to reflect ambulatory only eligibility. Updated Medical Necessity (Initial Approval) to align with current FDA labeling (revised 11/2025): clarified ambulatory-only eligibility, added/strengthened baseline documentation requirements and incorporated key safety-related “Limitations of Use” considerations. Coding Reviewed: no changes required. Administrative update to incorporate the new medical policy template. | 5/1/2026 | 5/6/2026 |
| Annual Review | Addition of statement: *Note: Use of Elevidys in non-ambulatory patients is still under review following FDA recommendation to halt shipment of this population on July 28, 2025. It is important to check status of regulatory oversight to confirm status of clinical use. Minimal changes. Coding reviewed: No changes. | 12/3/2025 | 12/11/2025 |
| Policy Inception | New Policy Creation | 12/9/2024 | 12/17/2024 |